Vitae Pharmaceuticals (VTAE) has risen sharply, recording gains of 198.43% in the past 4 weeks. However, the stock has corrected -0.1% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 200.04% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 33.53% and the 50-Day Moving Average is 79.8%.The 200 Day SMA reached 107.58%
Vitae Pharmaceuticals (NASDAQ:VTAE): The stock opened in the green at $20.95 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $20.98 and a low of $20.92 for the day. The stock did not find buyers even at the lows and closed at $20.92 recording a loss of -0.05%. 873,838 shares exchanged hands during the trading day. The stock had closed at $20.92 in the previous days trading.
Vitae Pharmaceuticals (VTAE) stock is expected to deviate a maximum of $4.92 from the average target price of $18.8 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $21 and the most muted being $10.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.